Osiris Therapeutics
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Osiris Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Osiris Therapeutics: 7 sponsored US clinical trials, none currently recruiting.
Osiris Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 6 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Leg Ulcer, with 1 trials.
Upper-quartile sponsor footprint
Osiris Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers
NCT03629236
TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers
NCT02936115
TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers
NCT02936128
GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers
NCT02675855
Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers
NCT02571738
GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds
NCT02260609
Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers
NCT01596920
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 5 |
Therapeutic Areas
How the Osiris Therapeutics archive is shaped
7 indexed studies, none listed as recruiting (0% open); 4 completed (57%).
Phase mix: 6 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Venous Leg Ulcer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Osiris Therapeutics: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Osiris Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Osiris Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Osiris Therapeutics or any single study.
- None of Osiris Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Venous Leg Ulcer is the condition Osiris Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Venous Leg Ulcer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Osiris Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.